Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine

Massimo Breccia, Luana Fianchi, Monia Lunghi, Gianluca Gaidano, Alessandro Levis, Carlo Finelli, Valeria Santini, Pellegrino Musto, Giovanna Mansueto, Esther N. Oliva, Pietro Leoni, Maria Antonietta Aloe Spiriti, Stefan Hohaus, Giuseppe Leone, Giuliana Alimena, Maria Teresa Voso

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1786-1787
Number of pages2
JournalLeukemia and Lymphoma
Volume54
Issue number8
DOIs
Publication statusPublished - Aug 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Breccia, M., Fianchi, L., Lunghi, M., Gaidano, G., Levis, A., Finelli, C., Santini, V., Musto, P., Mansueto, G., Oliva, E. N., Leoni, P., Spiriti, M. A. A., Hohaus, S., Leone, G., Alimena, G., & Voso, M. T. (2013). Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Leukemia and Lymphoma, 54(8), 1786-1787. https://doi.org/10.3109/10428194.2012.749406